The bill on the Biosimilar Red Tape Elimination Act reintroduced by Senator Mike Lee, backed by senators Ben Ray Lujan, Mike Braun and J.D. Vance, could have a significant impact if it becomes an Act.
Intending to amend existing legislation to state that all biosimilars, upon approval by the US Food and Drug Administration (FDA), shall be deemed interchangeable with biologics, it would pave
Scrip takes a look at what it would mean for pharmacists to have a greater say in biosimilar dispensing, what the generics substitution experience indicates, and which factors could negatively affect